{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:55:12Z","timestamp":1770994512210,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[1986,1,1]],"date-time":"1986-01-01T00:00:00Z","timestamp":504921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1986]]},"DOI":"10.1007\/bf00647446","type":"journal-article","created":{"date-parts":[[2004,11,27]],"date-time":"2004-11-27T19:56:35Z","timestamp":1101585395000},"page":"S25-S28","source":"Crossref","is-referenced-by-count":44,"title":["A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people"],"prefix":"10.1007","volume":"18","author":[{"given":"Ian","family":"Magrath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Sandlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Raynor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Arasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Miser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"4181","volume":"37","author":"W Bierbaum","year":"1981","unstructured":"Bierbaum W, Bremer K, Firusian N, Higi M, Niederle N, Scheulen ME, Schmidt CG, Seeber S (1981) Chemotherapeutische Behandlungsm\u00f6glichkeiten bei fortgeschrittenen Sarkomen. Dtsch Med Wochenschr 37: 4181?1185","journal-title":"Dtsch Med Wochenschr"},{"key":"CR2","first-page":"142","volume":"4","author":"V Bramwell","year":"1985","unstructured":"Bramwell V, Mouridsen H, Santoro A, Blackledge G, Somers R, Thomas D, Sylvester R, Bush H (1985) Cyclophosphamide vs Ifosfamide: a randomised phase II trial in adult soft tissue sarcoma. Preliminary report of the EORTc soft tissue and bone sarcoma group. Proc Amer Soc Clin Oncol 4: 142 (Abst C-556)","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"CR3","first-page":"4977","volume":"32","author":"N Brock","year":"1982","unstructured":"Brock N, Habs M, Pohl J, Schm\u00e4hl D, Stekar J (1982), Mesna (natrium-2-mercaptoethanesulphonate). Dtsch Therapiewoche 32: 4977?4996","journal-title":"Dtsch Therapiewoche"},{"key":"CR4","first-page":"29","volume":"14","author":"P Bruhl","year":"1976","unstructured":"Bruhl P, Gunther U, Hoefer-Janker H (1976) Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumors. Int J Clin Pharmacol 14: 29?39","journal-title":"Int J Clin Pharmacol"},{"key":"CR5","first-page":"14","volume":"9","author":"A Goldin","year":"1982","unstructured":"Goldin A (1982) Ifosfamide in experimental tumor systems. Semin Oncol 9: 14?23","journal-title":"Semin Oncol"},{"key":"CR6","first-page":"96","volume":"9","author":"HL Hunter","year":"1982","unstructured":"Hunter HL, Harrison EF (1982) The anticancer spectrum of ifosfamide. Semin Oncol 9: 96?100","journal-title":"Semin Oncol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-2008-1034070","volume":"195","author":"H Jurgens","year":"1983","unstructured":"Jurgens H, Csherati M, Gobel V, Gutjahr P, Jobke A, Kaatsch P, Kuhl J, Sekera J, Winkler K (1983) Die Kooperative Ewing-Sarkom-Studie CESS 81 der GPO: Zwischenbericht. Klin Padiatr 195: 207?213","journal-title":"Klin Padiatr"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/08880018409141708","volume":"1","author":"J Kraker de","year":"1984","unstructured":"Kraker J de, Voute PA (1984) Ifosfamide and vincristine in paediatric tumours. A Phase II study. Eur Pediatr Haematol Oncol 1: 47?50","journal-title":"Eur Pediatr Haematol Oncol"},{"key":"CR9","first-page":"240","volume":"4","author":"JS Miser","year":"1985","unstructured":"Miser JS, Steis R, Longo DL, Belasco JB, Triche TJ, Kinsella TJ (1985) Treatment of newly diagnosed high-risk sarcomas and primitive neuroectodermal tumors (PNET) in children and young adults. Proc Amer Soc Clin Oncol 4: 240 (Abst C-935)","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0305-7372(83)80013-9","volume":"10","author":"ME Scheulen","year":"1983","unstructured":"Scheulen ME, Niederle N, Bremer K, Sch\u00fctte J, Seeber S (1983) Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II study with 151 patients. Cancer Treat Rev 10: 93?101","journal-title":"Cancer Treat Rev"},{"key":"CR11","first-page":"69","volume":"11","author":"RC Stuart-Harris","year":"1983","unstructured":"Stuart-Harris RC, Harper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF, Wiltshaw E (1983) High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma. Cancer Chemother Pharmacol 11: 69?72","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR12","first-page":"159","volume":"4","author":"W Wellens","year":"1981","unstructured":"Wellens W, Donhuijsen-Ant R, Habets L, Kleinmanns G, Mussgnug G, Schroeder M, Westerhausen M (1981) Therapie progredienter Sarkome mit Etoposid und Ifosfamid. Aktuel Onkol 4: 159?164","journal-title":"Aktuel Onkol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00647446.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00647446\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00647446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T02:09:40Z","timestamp":1554430180000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00647446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986]]},"references-count":12,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[1986]]}},"alternative-id":["BF00647446"],"URL":"https:\/\/doi.org\/10.1007\/bf00647446","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986]]}}}